Join our expert panel—Prof. Nagaendran Kandiah (Singapore), Dr. Masanori Kurihara (Japan), and Prof. Ralph Martins (Australia)—for a dynamic, three-part discussion on ensuring the safe and effective administration of anti-amyloid therapies, with regional insights on ARIA management, treatment monitoring, and cross-disciplinary coordination in Alzheimer’s care.
Part A:
In this section, the expert panel discusses patient selection and pre-treatment risk assessment for anti-amyloid therapy. They address diagnostic confidence, the role of biomarkers like APOE4 genotyping, MRI findings as criteria for treatment, and comorbid conditions as contraindications for therapy.
Part B:
In this section, the expert panel discusses ARIA monitoring and management protocols. They address the recommended MRI monitoring schedule, classification and grading of ARIA, appropriate treatment modifications, and differentiation between symptomatic ARIA and infusion-related reactions.
Part C:
In this section, the expert panel discusses best practices for collaboration between neurologists and radiologists to ensure timely and accurate ARIA detection and reporting. They also cover how emergency departments should be prepared to recognize and manage symptomatic ARIA, especially in differentiating it from stroke.